Electroporation of mRNA as a Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins
Authors:
- 31 May 2024
- book chapter
- Published by Springer Nature
- Vol. 2786, 219-235
Abstract
Electroporation (EP) of mRNA into human cells is a broadly applicable method to transiently express proteins of choice in a variety of different cell types. We have spent more than two decades to optimize and adapt this method, first for antigen-loading of dendritic cells (DCs) and subsequently for T cells, B cells, bulk PBMCs, and several cell lines. In this regard, antigens were introduced, processed, and presented in context of MHC class I and II. Next to that, functional proteins like adhesion receptors, T-cell receptors (TCRs), chimeric antigen receptors (CARs), constitutively active signal transducers (i.e. caIKK), and others were successfully expressed. We have also established this protocol under full GMP compliance as part of a manufacturing license to produce mRNA-electroporated DCs and mRNA-electroporated T cells for therapeutic applications in clinical trials. Therefore, we here want to share our universal mRNA electroporation protocol and the experience we have gathered with this method. The advantages of the transfection method presented here are: (1) easy adaptation to different cell types; (2) scalability from 106 to approximately 108 cells per shot; (3) high transfection efficiency (80–99%); (4) homogenous protein expression; (5) GMP compliance if the EP is performed in a class A clean room; and (6) no transgene integration into the genome. The provided protocol involves: OptiMEM® as EP medium, a square-wave pulse with 500 V, and 4 mm cuvettes. To adapt the protocol to differently sized cells, simply the pulse time has to be altered. Thus, we share an overview of proven electroporation settings (including recovery media), which we have established for various cell types. Next to the basic protocol, we also provide an extensive list of hints and tricks, which, in our opinion, are of great value for everyone who intends to use this transfection technique.Keywords
This publication has 82 references indexed in Scilit:
- Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastasesCancer Immunology, Immunotherapy, 2014
- Concurrent interaction of DCs with CD4+ and CD8+ T cells improves secondary CTL expansion: It takes three to tangoEuropean Journal of Immunology, 2014
- Triggering of NF‐κB in cytokine‐matured human DCs generates superior DCs for T‐cell priming in cancer immunotherapyEuropean Journal of Immunology, 2014
- A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptorCancer Immunology, Immunotherapy, 2014
- Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formulaCancer Immunology, Immunotherapy, 2014
- CD8+ T-cell priming and boosting: more antigen-presenting DC, or more antigen per DC?Cancer Immunology, Immunotherapy, 2013
- Nonviral RNA Transfection to Transiently Modify T Cells with Chimeric Antigen Receptors for Adoptive Therapy2012
- Chimeric Antigen Receptors for T-Cell Based Therapy2012
- Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patientCancer Immunology, Immunotherapy, 2011
- Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodesCancer Immunology, Immunotherapy, 2007